Puma Biotechnology

365 articles with Puma Biotechnology

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2022

  5/11/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 9, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,500 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Reports First Quarter 2022 Financial Results

  5/5/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022.

• Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting

  4/27/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology Annual Meeting.

• Puma Biotechnology to Host Conference Call to Discuss First Quarter 2022 Financial Results

  4/21/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 5, 2022, following the release of its first quarter 2022 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Apr 05, 2022

  4/5/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on April 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,875 shares of Puma common stock to four new non-executive employees.

• Puma Biotechnology Announces $10 Million Private Placement

  3/10/2022

  Puma Biotechnology, Inc. announced that it has entered into a securities purchase agreement with Alan H Auerbach, the Company’s Chief Executive Officer, President and Chairman of the Board, as well as a fund of Athyrium Capital Management, LP.

• Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference

  3/7/2022

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel discussion on breast cancer at Cowen’s 42nd Annual Health Care Conference, which will be held virtually.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Mar 04, 2022

  3/4/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on March 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 9,375 shares of Puma common stock to one new non-executive employee.

• Puma Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results

  3/3/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2021.

• Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results

  2/16/2022

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 3, following release of its fourth quarter and full year 2021 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Feb 03, 2022

  2/3/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on February 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 24,375 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jan 20, 2022

  1/20/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on January 18, 2022 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 11,250 shares of Puma common stock to one new non-executive employee.

• Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer

  1/12/2022

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of breast cancer have been updated for 2022 and include two important changes involving neratinib (NERLYNX®).

• Puma Biotechnology Releases Updated Corporate Presentation

  1/10/2022

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, presented at the virtual H.C. Wainwright BioConnect Conference, which began at 7:00 a.m. EST on Monday, January 10, 2022.

• Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference

  1/4/2022

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright BioConnect Virtual Conference.

• Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting

  12/10/2021

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented an update from its Phase II SUMMIT trial at the ongoing 2021 San Antonio Breast Cancer Symposium (SABCS) Annual Meeting.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Dec 03, 2021

  12/3/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on December 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 13,125 shares of Puma common stock to two new non-executive employees.

• Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)

  11/23/2021

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S. Patent No. 7,399,865, extending the patent term five (5) years.

• Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting

  11/20/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of Innovative Glioblastoma Therapy at the 2021 Society for Neuro-Oncology Annual Meeting.

• Puma Biotechnology Reports Third Quarter 2021 Financial Results

  11/4/2021

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2021.